EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
17.74
+1.02 (6.10%)
At close: Dec 5, 2025, 4:00 PM EST
17.85
+0.11 (0.62%)
Pre-market: Dec 8, 2025, 4:09 AM EST
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover EyePoint Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $29.6, which forecasts a 66.85% increase in the stock price over the next year. The lowest target is $23 and the highest is $39.
Price Target: $29.6 (+66.85%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 5 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $28 → $39 | Buy | Maintains | $28 → $39 | +119.84% | Nov 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +52.20% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $23 | Strong Buy | Maintains | $22 → $23 | +29.65% | Aug 6, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $28 | Buy | Initiates | $28 | +57.84% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +24.01% | May 29, 2025 |
Financial Forecast
Revenue This Year
32.44M
from 43.27M
Decreased by -25.03%
Revenue Next Year
10.90M
from 32.44M
Decreased by -66.40%
EPS This Year
-3.09
from -2.32
EPS Next Year
-2.92
from -3.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.6M | 47.3M | ||||
| Avg | 32.4M | 10.9M | ||||
| Low | 30.2M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -13.1% | 45.6% | ||||
| Avg | -25.0% | -66.4% | ||||
| Low | -30.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.90 | -2.09 | ||||
| Avg | -3.09 | -2.92 | ||||
| Low | -3.14 | -3.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.